Customize this page|
1
Votes
vote
UCB and AstraZeneca form alliance for the commercialization of Cimzia(R) in BrazilBRUSSELS, BELGIUM--(Marketwire - September 28, 2009) - UCB and AstraZeneca announced today that they have entered into a partnership to register and commercialize UCB's PEGylated anti-TNF alpha drug Cimzia® (certolizumab pegol) in Brazil. The drug is to be registered for the treatment of rh... |
|
2
Votes
vote
UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE)BRUSSELS, BELGIUM and MORRIS PLAINS, NJ--(Marketwire - August 27, 2009) - * Data from phase IIb dose and regimen-ranging study demonstrate clinically meaningful treatment effect * Treatment advantage of epratuzumab over placebo reached 24.9% at week 12 Brussels, Belgium & Mor... |
